Liquidia Shares Climb to All-Time High Amid Surging Revenue

Dow Jones

05/12

By Christopher Kuo

Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue.

Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday.

The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share.

Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said.

The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 11, 2026 12:36 ET (16:36 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2634235023"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634235023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634235023?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634235023","market":"nz","top_or_hot":-1,"title":"Liquidia Shares Climb to All-Time High Amid Surging Revenue","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n</p>\n<p>\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n</p>\n<p>\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n</p>\n<p>\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 11, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liquidia Shares Climb to All-Time High Amid Surging Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiquidia Shares Climb to All-Time High Amid Surging Revenue\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-05-12 00:36</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n</p>\n<p>\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n</p>\n<p>\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n</p>\n<p>\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n</p>\n<p>\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 11, 2026 12:36 ET (16:36 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LQDA","symbol_name":"Liquidia Technologies Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634235023","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634235023","pubTimestamp":1778517360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue.Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday.The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share.Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said.The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LQDA":"Liquidia Technologies Inc","BK4007":"制药"},"translate_title":"收入激增，Liquidia股价攀升至历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LQDA":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Liquidia shares rose to an all-time high as the company's product sales drove a surge in first-quarter revenue. \n\n\n  Shares of the biopharmaceutical company focused on cardiopulmonary diseases rose 17% on Monday to $49.56. The stock reached an all-time high of $50.50 on Monday. \n\n\n  The company posted a first-quarter profit of $52.9 million, or 52 cents a share, compared with a profit of $38.4 million, or 45 cents a share, a year earlier. Analysts polled by FactSet expected 41 cents a share. \n\n\n  Revenue climbed to $132.9 million from $3.1 million a year earlier. Analysts expected $119.4 million. The growth was driven by sales of the Yutrepia treatment for pulmonary hypertension. Product sales of Yutrepia were $129.9 million in the quarter, the company said. \n\n\n  The company began shipping Yutrepia to U.S. customers in June, following approval by the Food and Drug Administration on May 23, 2025. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 12:36 ET (16:36 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}